Novartis Oncology is committed to developing innovative cancer medicines and improving access to treatment through patient assistance and cancer resource programs. We are continually exploring new commercial and access models to best meet the needs of cancer patients and adapt to changing healthcare environments.
Novartis Oncology Access
Novartis Oncology Access (NOA) is a sustainable access solution through which Novartis shares the cost of its medicines with government healthcare systems, charities and other payers, or directly with patients without healthcare coverage who are unable to pay for the full cost of their medication. We believe that through this partnership-based approach, we can extend affordable access to a broader number of patients in a sustainable manner.
NOA is designed to improve access in countries with very limited healthcare reimbursement systems. Today, NOA offers assistance to emerging nations in Asia, the Middle East, Central and Eastern Europe, Africa and Latin America that have challenging healthcare environments.
The Glivec International Patient Assistance Program
In 2002, Novartis Oncology introduced the Glivec International Patient Assistance Program (GIPAPTM). This program, one of the most far-reaching patient assistance programs ever implemented on a global scale, is active in over 80 low- to middle-income countries, and donates to patients who are not insured, not reimbursed, cannot pay for the treatment privately and are in countries that have minimal reimbursement capabilities.